M
Marie-Anne Valentin
Researcher at Novartis
Publications - 18
Citations - 883
Marie-Anne Valentin is an academic researcher from Novartis. The author has contributed to research in topics: Tolerability & Secukinumab. The author has an hindex of 10, co-authored 16 publications receiving 537 citations.
Papers
More filters
Journal ArticleDOI
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
Elisabeth H. Thijssen,Renaud La Joie,Amelia Strom,Corrina Fonseca,Leonardo Iaccarino,Amy Wolf,Salvatore Spina,Isabel E. Allen,Yann Cobigo,Hilary W. Heuer,Lawren VandeVrede,Nicholas K. Proctor,Argentina Lario Lago,Suzanne L. Baker,Rajeev Sivasankaran,Agnieszka Kieloch,Arvind Kinhikar,Lili Yu,Marie-Anne Valentin,Andreas Jeromin,Henrik Zetterberg,Oskar Hansson,Niklas Mattsson-Carlgren,Danielle Graham,Kaj Blennow,Joel H. Kramer,Lea T. Grinberg,William W. Seeley,Howard J. Rosen,Bradley F. Boeve,Bruce L. Miller,Charlotte E. Teunissen,Gil D. Rabinovici,Julio C. Rojas,Jeffrey L. Dage,Adam L. Boxer,Treatment for Frontotemporal Lobar Degeneration investigators +36 more
TL;DR: In this article, the diagnostic value of both biomarkers in cognitively unimpaired participants and patients with a clinical diagnosis of mild cognitive impairment, Alzheimer's disease syndromes, or frontotemporal lobar degeneration (FTLD) was compared.
Journal ArticleDOI
β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis
Frank Kolbinger,Christian Loesche,Marie-Anne Valentin,Xiaoyu Jiang,Yi Cheng,Philip Jarvis,Thomas Peters,Claudio Calonder,Gerard Bruin,Florine Polus,Birgit Aigner,David M. Lee,Manfred Bodenlenz,Frank Sinner,Thomas R. Pieber,Dhavalkumar D. Patel +15 more
TL;DR: Defensin 2 (BD‐2) was identified as a biomarker of IL‐17A–driven pathology by comparing protein expression in patients with psoriasis versus that in healthy subjects, and it was found that BD‐2 levels are most highly increased in customers with psoriatic skin lesions.
Journal ArticleDOI
Validation of immunoassay for protein biomarkers: Bioanalytical study plan implementation to support pre-clinical and clinical studies
TL;DR: This paper describes the implementation of a bioanalytical study plan for the validation of immunoassays to support decision-making biomarkers and biomarker selection during preclinical and clinical studies and defines milestones and decision points to be followed during the assay validation.
Journal ArticleDOI
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Thomas Dörner,Maximilian G. Posch,Yue Li,Olivier Petricoul,Maciej Cabanski,Julie Milojevic,Esther Kamphausen,Marie-Anne Valentin,Claudia Simonett,Louise Mooney,Andreas Hüser,Hermann Gram,Frank Wagner,Stephen John Oliver +13 more
TL;DR: Overall results in this single-dose study suggest potent and sustained B cell depletion by ianalumab could provide therapeutic benefits in patients with pSS without major side effects.
Journal ArticleDOI
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects
Thomas Langenickel,Chiaki Tsubouchi,Surya Ayalasomayajula,Parasar Pal,Marie-Anne Valentin,Markus Hinder,Stanford Jhee,Hakop Gevorkyan,Iris Rajman +8 more
TL;DR: In this article, the potential effects of LCZ696 on cerebrospinal fluid (CSF) concentrations of Aβ isoforms in healthy human volunteers were assessed, and it was shown that the potential exists that treatment of LZ696, through the inhibition of neprilysin by LBQ657 (an LCZ-696 metabolite), may result in accumulation of amyloid-β.